Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Caribou Biosciences ( (CRBU) ).
Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025. Ryali, with 20 years of experience in the biopharmaceutical industry, will oversee strategic leadership in corporate finance, investor relations, and corporate communications. His appointment is timed with the company’s advancement of four clinical-stage programs and the disclosure of multiple datasets in 2025. Ryali’s extensive background in finance roles at several biopharmaceutical companies is expected to support Caribou’s ongoing efforts to deliver off-the-shelf CAR-T cell therapies to patients.
More about Caribou Biosciences
Caribou Biosciences is a clinical-stage biopharmaceutical company specializing in CRISPR genome-editing technologies. The company focuses on developing transformative therapies for patients with hematologic malignancies and autoimmune diseases, utilizing its Cas12a chRDNA technology to enhance precision in genome editing.
Average Trading Volume: 1,417,431
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $144M
Learn more about CRBU stock on TipRanks’ Stock Analysis page.
